Pilot study of fludarabine (F), cyclophosphamide (C), and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Keating, AR [1 ]
O'Brien, SM [1 ]
Cortes, JE [1 ]
Thomas, D [1 ]
Koller, C [1 ]
Beran, M [1 ]
Kantarjian, HM [1 ]
Keating, MJ [1 ]
Giles, FJ [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1401
引用
收藏
页码：313A / 313A
页数：1
相关论文
共 50 条
  • [1] Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
    Francis J. Giles
    Gary Guangping Shi
    Jorge E. Cortes
    Deborah Thomas
    Anna R. Keating
    Hagop M. Kantarjian
    Michael J. Keating
    Susan M. O'Brien
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 223 - 228
  • [2] Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
    Giles, FJ
    Shi, GGP
    Cortes, JE
    Thomas, D
    Keating, AR
    Kantarjian, HM
    Keating, MJ
    O'Brien, SM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (03) : 223 - 228
  • [3] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [4] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [5] Fludarabine (FAMP) and cyclophosphamide (CTX) combination in chronic lymphocytic leukemia (CLL).
    Gonzalez, H
    Cazin, B
    Dighiero, G
    Merle-Béral, H
    Vernant, JP
    Binet, JL
    Maloum, K
    BLOOD, 1998, 92 (10) : 277B - 277B
  • [6] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL)
    OBrien, S
    Kantarjian, H
    Beran, M
    Lerner, S
    Gilbreath, J
    Keating, MJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 453 - 453
  • [7] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Freireich, E
    Komblau, S
    Koller, C
    Lerner, S
    Gilbreath, J
    Keating, M
    BLOOD, 1996, 88 (10) : 1910 - 1910
  • [8] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
    Grifi, Fatiha
    Bougherira, Soraya
    Djenouni, Amel
    LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
  • [9] Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).
    Tedeschi, A
    Montillo, M
    Miqueleiz, S
    Draisci, M
    Ricci, F
    Scarpati, B
    Mura, ME
    Crugnola, M
    Morra, E
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [10] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE STUDY
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Ionita, M.
    Calamar, D.
    Ionita, C. O.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 526 - 526
12345